Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NRXP

NRX Pharmaceuticals Inc

Last Close
May 10 • 10:08AM ET
2.92
Dollar change
-0.01
Percentage change
-0.34 		%
Held by: VTI PSIL VXF Scroll to Statements
Index- P/E- EPS (ttm)-1.54 Insider Own20.20% Shs Outstand8.39M Perf Week39.05%
Market Cap27.94M Forward P/E- EPS next Y-2.10 Insider Trans0.00% Shs Float7.64M Perf Month-46.91%
Income-30.16M PEG- EPS next Q-0.55 Inst Own4.20% Short Float6.36% Perf Quarter-42.97%
Sales0.00M P/S- EPS this Y45.50% Inst Trans- Short Ratio1.13 Perf Half Y-17.95%
Book/sh-1.40 P/B- EPS next Y3.67% ROA-182.00% Short Interest0.49M Perf Year-53.28%
Cash/sh0.48 P/C6.09 EPS next 5Y- ROE-682.61% 52W Range1.90 - 12.00 Perf YTD-36.52%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-75.67% Beta1.21
Dividend TTM- Quick Ratio0.36 Sales past 5Y0.00% Gross Margin- 52W Low53.68% ATR (14)0.55
Dividend Ex-Date- Current Ratio0.36 EPS Y/Y TTM32.86% Oper. Margin0.00% RSI (14)42.73 Volatility25.17% 15.27%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price50.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-235.69% Payout- Rel Volume0.72 Prev Close2.93
Sales Surprise- EPS Surprise28.57% Sales Q/Q- EarningsMay 14 AMC Avg Volume430.37K Price2.92
SMA20-9.46% SMA50-34.13% SMA200-21.37% Trades Volume44,435 Change-0.34%
May-08-24 09:55AM
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
(ACCESSWIRE)
08:30AM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
(PR Newswire)
May-07-24 04:01PM
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
(PR Newswire) -8.17%
May-06-24 08:30AM
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
(PR Newswire) +45.71%
Apr-30-24 08:30AM
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
(PR Newswire) -27.32%
08:56AM Loading…
Apr-18-24 08:56AM
Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
(InvestorPlace) -27.75%
08:32AM
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
(PR Newswire)
08:30AM
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
(PR Newswire)
Apr-17-24 04:45PM
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
(PR Newswire)
08:30AM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
(PR Newswire)
Apr-15-24 08:30AM
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
(PR Newswire)
Apr-08-24 08:30AM
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
(PR Newswire)
Apr-04-24 12:00PM
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
(Zacks) +9.70%
Apr-02-24 10:33AM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Apr-01-24 08:28AM
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(PR Newswire) +11.25%
10:53PM Loading…
Mar-28-24 10:53PM
NRXP Stock Earnings: NRX Pharmaceuticals Beats EPS for Q4 2023
(InvestorPlace) -10.96%
08:03AM
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
(PR Newswire)
08:00AM
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
(PR Newswire)
Mar-26-24 04:03PM
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
(PR Newswire)
Mar-25-24 08:30AM
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
(PR Newswire) -5.36%
Mar-21-24 04:02PM
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
(PR Newswire)
01:57PM
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
(PR Newswire)
Mar-18-24 08:30AM
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
(PR Newswire) +13.16%
Mar-12-24 07:49AM
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
(PR Newswire) -34.32%
Mar-11-24 08:30AM
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
(PR Newswire) +9.06%
Mar-04-24 08:30AM
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
(PR Newswire) +18.69%
Mar-01-24 08:30AM
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
(PR Newswire) +22.03%
Feb-27-24 10:49AM
/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./
(PR Newswire) -31.24%
08:54AM
NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million
(PR Newswire)
08:31AM
Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today?
(InvestorPlace)
04:01PM Loading…
Feb-26-24 04:01PM
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
(PR Newswire)
08:30AM
NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
(PR Newswire)
Feb-20-24 08:30AM
NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
(PR Newswire)
Feb-12-24 08:30AM
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)
(PR Newswire) -6.25%
Feb-09-24 08:30AM
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
(PR Newswire) +10.34%
Feb-05-24 06:48AM
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon
(PR Newswire) +5.28%
Jan-22-24 06:48AM
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
(PR Newswire)
Jan-17-24 06:48AM
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination
(PR Newswire)
Jan-16-24 06:48AM
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
(PR Newswire)
Jan-02-24 08:45AM
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco
(PR Newswire) +8.48%
06:48AM
NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard
(PR Newswire)
Dec-27-23 06:48AM
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
(PR Newswire)
Dec-19-23 08:15AM
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression
(PR Newswire) -7.34%
Dec-18-23 06:48AM
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
(PR Newswire) +24.19%
Dec-13-23 04:02PM
NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders
(PR Newswire)
Dec-11-23 06:48AM
NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event
(PR Newswire)
Nov-27-23 04:01PM
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference
(PR Newswire)
Nov-16-23 02:07PM
NRx Pharmaceuticals founder unveils potential treatment for suicidal thoughts and depression
(News Direct) -6.86%
09:32AM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-13-23 06:39PM
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
(PR Newswire)
Nov-07-23 06:48AM
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023
(PR Newswire)
Nov-06-23 06:48AM
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression
(PR Newswire) +5.22%
Oct-31-23 06:48AM
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression
(PR Newswire)
Oct-26-23 06:48AM
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain
(PR Newswire) +6.71%
Oct-12-23 06:48AM
NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference
(PR Newswire) +6.54%
Oct-05-23 06:48AM
NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference
(PR Newswire)
Oct-02-23 06:48AM
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain
(PR Newswire) +10.42%
Sep-21-23 09:35AM
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
(GlobeNewswire)
Sep-20-23 06:47AM
NRx Pharmaceuticals Publishes Shareholder Update Letter
(PR Newswire)
Sep-19-23 09:00AM
Sidoti Events, LLCs Virtual September Small-Cap Conference
(ACCESSWIRE)
Sep-18-23 06:46AM
NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference
(PR Newswire) -9.72%
Sep-15-23 06:46AM
NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression
(PR Newswire) +10.17%
Sep-14-23 04:01PM
NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support
(PR Newswire)
Sep-07-23 06:47AM
NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(PR Newswire) -8.24%
Sep-06-23 10:55AM
NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens
(PR Newswire)
Aug-30-23 06:47AM
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
(PR Newswire)
Aug-29-23 06:54AM
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share
(PR Newswire) +12.36%
Aug-14-23 04:01PM
NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
(PR Newswire)
Aug-07-23 06:47AM
NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023
(PR Newswire) -6.46%
06:47AM
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101 for Chronic Pain
(PR Newswire)
Jun-20-23 04:01PM
NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
(PR Newswire)
Jun-09-23 08:45AM
NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering
(PR Newswire)
Jun-06-23 12:20PM
NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering
(PR Newswire) -18.75%
Jun-02-23 02:19PM
NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023
(PR Newswire) +21.92%
May-16-23 06:47AM
NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
(PR Newswire) -7.26%
May-10-23 04:05PM
NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call
(PR Newswire)
Apr-27-23 04:01PM
NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
(PR Newswire)
Mar-30-23 04:01PM
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
(PR Newswire)
Mar-27-23 06:47AM
NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
(PR Newswire)
Mar-17-23 06:47AM
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
(PR Newswire)
Mar-09-23 06:47AM
NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering
(PR Newswire)
Feb-22-23 06:47AM
NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio
(PR Newswire)
Feb-13-23 06:47AM
NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality
(PR Newswire)
Feb-02-23 06:47AM
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
(PR Newswire) +5.93%
Jan-19-23 06:47AM
NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
(PR Newswire)
Jan-05-23 06:47AM
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
(PR Newswire) -6.78%
Jan-03-23 06:47AM
NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted
(PR Newswire) +9.01%
Dec-20-22 01:30AM
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
(PR Newswire) +6.54%
Dec-05-22 06:47AM
NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
(PR Newswire)
Dec-02-22 06:47AM
NRx Receives Nasdaq Notice of Listing Compliance
(PR Newswire) -6.76%
Nov-14-22 06:47AM
NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
(PR Newswire) -9.99%
01:30AM
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
(ACCESSWIRE)
Nov-10-22 06:47AM
NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022
(PR Newswire)
Nov-09-22 06:47AM
NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process
(PR Newswire)
Nov-07-22 06:47AM
NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing
(PR Newswire) +6.61%
Sep-08-22 06:40AM
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference
(PR Newswire) +10.53%
Aug-22-22 12:09PM
NRx, Relief Therapeutics reach tentative agreement to resolve litigation tied to Covid-19 therapy candidate
(American City Business Journals)
06:00AM
RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION
(PR Newswire)
Aug-15-22 06:50AM
NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise
(PR Newswire) -6.29%
Aug-10-22 12:41PM
/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./
(PR Newswire)
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hurvitz ChaimDirectorAug 30 '23Buy0.2970,00020,125570,000Sep 11 09:15 AM
Gorovitz AaronDirectorAug 30 '23Buy0.3235,00011,196105,000Sep 11 09:19 AM
Javitt Jonathan CChief ScientistAug 23 '23Buy0.33100,00033,000446,332Aug 24 12:14 PM
Javitt Jonathan CChief ScientistAug 22 '23Buy0.32200,00064,400346,332Aug 23 09:24 AM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.